Drug Trial Radar · NCT05905328
Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Dec 28, 2023
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- CytoAgents, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with lymphoma or multiple myeloma who are scheduled to receive CAR T-cell therapy. The first phase of the study is open label with dose escalation. Participants will start taking CTO1681 either the day before starting lymphodepleting chemotherapy or just prior to receiving their CAR T-cell therapy, depending on their cohort assignment. In both cases participants will continue to take the study drug three times daily until 13 days after their CAR T-cell infusion.
Conditions
- Cytokine Release Syndrome
Interventions
CTO1681 10 µgDrug
Administered 3 times daily for 15 days (initial cohort).
CTO1681 20 μgDrug
Administered 3 times daily for 15 days (successive cohort).
CTO1681 30 μgDrug
Administered 3 times daily for 15 days (successive cohort).
CTO1681 10 µg Run-in / 20 µg TreatmentDrug
Administered 3 times daily for up to 21 days (successive cohort).
CTO1681 20 µg Run-in / 30 µg TreatmentDrug
Administered three times daily for up to 21 days (successive cohort).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: 6 months following start of treatment
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of California, Irvine - Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Georgia Cancer Center at Augusta University
Augusta, Georgia · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.